天风证券给予健友股份买入评级海外制剂业务持续发展生物药启航在即目标价格为18.15元

每日经济新闻10-08

天风证券10月08日发布研报称，给予健友股份（603707.SH）买入评级，目标价格为18.15元。评级理由主要包括：1）肝素原料药：全球肝素原料龙头，价格逐步企稳；2）制剂：注射剂国际化能力领先，驱动业绩高速成长；3）生物药：多元化高效切入生物药市场，有望带动业绩加速增长。风险提示：原料药价格波动风险、无菌注射剂开发与审批波动风险、海外市场竞争风险、新药研发、上市进度不及预期风险、监管风险。AI...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2473494423?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-08 13:48","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2473494423","market":"us","top_or_hot":-1,"title":"天风证券给予健友股份买入评级 海外制剂业务持续发展 生物药启航在即 目标价格为18.15元","media":"每日经济新闻","content":"<div>\n<p>天风证券10月08日发布研报称，给予健友股份（603707.SH）买入评级，目标价格为18.15元。评级理由主要包括：1）肝素原料药：全球肝素原料龙头，价格逐步企稳；2）制剂：注射剂国际化能力领先，驱动业绩高速成长；3）生物药：多元化高效切入生物药市场，有望带动业绩加速增长。风险提示：原料药价格波动风险、无菌注射剂开发与审批波动风险、海外市场竞争风险、新药研发、上市进度不及预期风险、监管风险。AI...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvnkx0816685.shtml\">网页链接</a>\n\n</div>\n","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天风证券给予健友股份买入评级 海外制剂业务持续发展 生物药启航在即 目标价格为18.15元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天风证券给予健友股份买入评级 海外制剂业务持续发展 生物药启航在即 目标价格为18.15元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-08 13:48 北京时间&nbsp;&nbsp;&nbsp;<a href=https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvnkx0816685.shtml><strong>每日经济新闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>天风证券10月08日发布研报称，给予健友股份（603707.SH）买入评级，目标价格为18.15元。评级理由主要包括：1）肝素原料药：全球肝素原料龙头，价格逐步企稳；2）制剂：注射剂国际化能力领先，驱动业绩高速成长；3）生物药：多元化高效切入生物药市场，有望带动业绩加速增长。风险提示：原料药价格波动风险、无菌注射剂开发与审批波动风险、海外市场竞争风险、新药研发、上市进度不及预期风险、监管风险。AI...</p>\n\n<a href=\"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvnkx0816685.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159839","symbol_name":"生物药","start_time":0,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvnkx0816685.shtml","article_id":"2473494423","we_media_id":null,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2024-10-08/doc-incrvnkx0816685.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2473494423","pubTimestamp":1728366480,"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"天风证券10月08日发布研报称，给予健友股份（603707.SH）买入评级，目标价格为18.15元。评级理由主要包括：1）肝素原料药：全球肝素原料龙头，价格逐步企稳；2）制剂：注射剂国际化能力领先，驱动业绩高速成长；3）生物药：多元化高效切入生物药市场，有望带动业绩加速增长。风险提示：原料药价格波动风险、无菌注射剂开发与审批波动风险、海外市场竞争风险、新药研发、上市进度不及预期风险、监管风险。AI点评：健友股份近一个月获得1份券商研报关注，买入1家，平均目标价为18.15元。（文章来源：每日经济新闻）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":["rate"],"viewcount":null,"language":"zh","relate_stocks":{"159839":"生物药","601162":"天风证券","603707":"健友股份"},"translate_title":"Tianfeng Securities gave Jianyou shares a buy rating, the overseas preparation business continues to develop, and biopharmaceuticals are about to set sail, with a target price of 18.15 yuan","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159839":1,"601162":1,"603707":1},"content_text":"天风证券10月08日发布研报称，给予健友股份（603707.SH）买入评级，目标价格为18.15元。评级理由主要包括：1）肝素原料药：全球肝素原料龙头，价格逐步企稳；2）制剂：注射剂国际化能力领先，驱动业绩高速成长；3）生物药：多元化高效切入生物药市场，有望带动业绩加速增长。风险提示：原料药价格波动风险、无菌注射剂开发与审批波动风险、海外市场竞争风险、新药研发、上市进度不及预期风险、监管风险。AI点评：健友股份近一个月获得1份券商研报关注，买入1家，平均目标价为18.15元。（文章来源：每日经济新闻）\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2473494423"}

天风证券给予健友股份买入评级 海外制剂业务持续发展 生物药启航在即 目标价格为18.15元

精彩评论

天风证券给予健友股份买入评级海外制剂业务持续发展生物药启航在即目标价格为18.15元